Industry influence over clinical trial design and reporting lacks transparency

Although it is widely known that drug and device makers fund most clinical trials, a new analysis finds these companies are not always transparent about the influence they exert on trial design and reporting. And the researchers suggest business concerns may too often trump patient interests.

On the plus side, the analysis found the vast majority of academics and their industry partners, including contract research organizations, contributed to trial design and reporting. And four of five academics had complete access to all of the data generated by the trials that were examined, according to the analysis, which was published in BMJ.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


Source link

Leave a Reply

Your email address will not be published.